Koichi Kameda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Koichi Kameda has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Mady Malheiros Barbeitas
Fundação Oswaldo Cruz, Brazil; French National Centre for Scientific Research, France
3 shared publications - Alila Brossard Antonielli
Humboldt University of Berlin, Germany
2 shared publications - Gabriela Costa Chaves
Fundação Oswaldo Cruz, Brazil
2 shared publications - Marilena Cordeiro Dias Villela Corrêa
Universidade do Estado do Rio de Janeiro, Brazil
2 shared publications - Maurice Cassier
CNRS
2 shared publications - Alice Street
School of Social and Political Science, University of Edinburgh, Edinburgh EH8 9LD, UK
1 shared publication
Latest Publications
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Testing the Nation : Healthcare policy and innovation in diagnostics for infectious diseases in Brazil
Tester la Nation : politiques de santé et l'innovation technologique pour le diagnostic des maladies infectieuses au Brésil: Le diagnostic in vitro (DIV) est un segment des biotechnologies de santé pour lequel les principaux acteurs se situent dans les pays développés. Parallèlement, le paysage actuel a contraint les compagnies multinationales à transformer leur modèle économique, tout en obligeant les pays non-occidentaux à devenir de nouveaux marchés et des lieux où de nouveaux savoirs et technologies pourraient être produits. Non seulement le Brésil est un marché important en ce qui concerne les produits de santé, mais il possède aussi une longue histoire en matière de fabrication de produits biologiques et pharmaceutiques. Dans ce contexte que les acteurs brésiliens se sont engagés dans production de DIV pour les maladies infectieuses. Ces initiatives articulent la santé publique et les politiques économiques industrielles, soit l’approche qui a été privilégiée dans le cadre du courant néo-développementaliste (neo-desenvolvimentismo) prôné de 2003 à 2016 dans ce pays. Cette thèse a pour objectif d’éclairer le travail des acteurs qui ont organisé la production et l’innovation de DIV dans un monde en mouvement, et dont le positionnement se situe au croisement de questions relevant de la santé publique, de l’autonomie technologique et de l’économie nationale brésilienne. Cette recherche se fonde sur un travail de terrain conduit entre 2014 et 2017, qui inclut des stages dans deux laboratoires rattachés à la fondation Oswaldo Cruz, ainsi que des entretiens avec de nombreux acteurs impliqués dans la production de ces tests diagnostics nationaux.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Testing the Nation : Healthcare policy and innovation in diagnostics for infectious diseases in Brazil
Tester la Nation : politiques de santé et l'innovation technologique pour le diagnostic des maladies infectieuses au Brésil: Le diagnostic in vitro (DIV) est un segment des biotechnologies de santé pour lequel les principaux acteurs se situent dans les pays développés. Parallèlement, le paysage actuel a contraint les compagnies multinationales à transformer leur modèle économique, tout en obligeant les pays non-occidentaux à devenir de nouveaux marchés et des lieux où de nouveaux savoirs et technologies pourraient être produits. Non seulement le Brésil est un marché important en ce qui concerne les produits de santé, mais il possède aussi une longue histoire en matière de fabrication de produits biologiques et pharmaceutiques. Dans ce contexte que les acteurs brésiliens se sont engagés dans production de DIV pour les maladies infectieuses. Ces initiatives articulent la santé publique et les politiques économiques industrielles, soit l’approche qui a été privilégiée dans le cadre du courant néo-développementaliste (neo-desenvolvimentismo) prôné de 2003 à 2016 dans ce pays. Cette thèse a pour objectif d’éclairer le travail des acteurs qui ont organisé la production et l’innovation de DIV dans un monde en mouvement, et dont le positionnement se situe au croisement de questions relevant de la santé publique, de l’autonomie technologique et de l’économie nationale brésilienne. Cette recherche se fonde sur un travail de terrain conduit entre 2014 et 2017, qui inclut des stages dans deux laboratoires rattachés à la fondation Oswaldo Cruz, ainsi que des entretiens avec de nombreux acteurs impliqués dans la production de ces tests diagnostics nationaux.
- Open Access
- 7 February 2024
- Published by Springer Nature in BMC Health Services Research
- Vol. 24 (1) , 1-13
Is qualitative social research in global health fulfilling its potential?: a systematic evidence mapping of research on point-of-care testing in low- and middle-income contexts
Background: Qualitative social research has made valuable contributions to understanding technology-based interventions in global health. However, we have little evidence of who is carrying out this research, where, how, for what purpose, or the overall scope of this body of work. To address these questions, we undertook a systematic evidence mapping of one area of technology-focused research in global health, related to the development, deployment and use of point-of-care tests (POCTs) for low-and middle-income countries (LMICs). Methods: We conducted an exhaustive search to identify papers reporting on primary qualitative studies that explore the development, deployment, and use of POCTs in LMICs and screened results to identify studies meeting the inclusion criteria. Data were extracted from included studies and descriptive analyses were conducted. Results: One hundred thirty-eight studies met our inclusion criteria, with numbers increasing year by year. Funding of studies was primarily credited to high income country (HIC)-based institutions (95%) and 64% of first authors were affiliated with HIC-based institutions. Study sites, in contrast, were concentrated in a small number of LMICs. Relatively few studies examined social phenomena related to POCTs that take place in HICs. Seventy-one percent of papers reported on studies conducted within the context of a trial or intervention. Eighty percent reported on studies considering POCTs for HIV and/or malaria. Studies overwhelmingly reported on POCT use (91%) within primary-level health facilities (60%) or in hospitals (30%) and explored the perspectives of the health workforce (70%). Conclusions: A reflexive approach to the role, status, and contribution of qualitative and social science research is crucial to identifying the contributions it can make to the production of global health knowledge and understanding the roles technology can play in achieving global health goals. The body of qualitative social research on POCTs for LMICs is highly concentrated in scope, overwhelmingly focuses on testing in the context of a narrow number of donor-supported initiatives and is driven by HIC resources and expertise. To optimise the full potential of qualitative social research requires the promotion of open and just research ecosystems that broaden the scope of inquiry beyond established public health paradigms and build social science capacity in LMICs.
- 7 February 2024
- Published by Springer Nature in BMC Health Services Research
- Vol. 24 (1) , 1-13
Open AccessIs qualitative social research in global health fulfilling its potential?: a systematic evidence mapping of research on point-of-care testing in low- and middle-income contexts
Background: Qualitative social research has made valuable contributions to understanding technology-based interventions in global health. However, we have little evidence of who is carrying out this research, where, how, for what purpose, or the overall scope of this body of work. To address these questions, we undertook a systematic evidence mapping of one area of technology-focused research in global health, related to the development, deployment and use of point-of-care tests (POCTs) for low-and middle-income countries (LMICs). Methods: We conducted an exhaustive search to identify papers reporting on primary qualitative studies that explore the development, deployment, and use of POCTs in LMICs and screened results to identify studies meeting the inclusion criteria. Data were extracted from included studies and descriptive analyses were conducted. Results: One hundred thirty-eight studies met our inclusion criteria, with numbers increasing year by year. Funding of studies was primarily credited to high income country (HIC)-based institutions (95%) and 64% of first authors were affiliated with HIC-based institutions. Study sites, in contrast, were concentrated in a small number of LMICs. Relatively few studies examined social phenomena related to POCTs that take place in HICs. Seventy-one percent of papers reported on studies conducted within the context of a trial or intervention. Eighty percent reported on studies considering POCTs for HIV and/or malaria. Studies overwhelmingly reported on POCT use (91%) within primary-level health facilities (60%) or in hospitals (30%) and explored the perspectives of the health workforce (70%). Conclusions: A reflexive approach to the role, status, and contribution of qualitative and social science research is crucial to identifying the contributions it can make to the production of global health knowledge and understanding the roles technology can play in achieving global health goals. The body of qualitative social research on POCTs for LMICs is highly concentrated in scope, overwhelmingly focuses on testing in the context of a narrow number of donor-supported initiatives and is driven by HIC resources and expertise. To optimise the full potential of qualitative social research requires the promotion of open and just research ecosystems that broaden the scope of inquiry beyond established public health paradigms and build social science capacity in LMICs.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Cadernos de Saude Publica
- Vol. 39 (9) , e00073623
Rumo à equidade em saúde: por uma agenda de pesquisa e desenvolvimento e produção local orientada pelas múltiplas necessidades do Sistema Único de Saúde
Em seu discurso de posse, no dia 2 de janeiro de 2023, a nova ministra da saúde, Nísia Trindade Lima, apontou a produção local de insumos e o reforço do Complexo Econômico-Industrial da Saúde (CEIS, acronym in Portuguese) como algumas de suas prioridades, além da retomada do papel de coordenação do Ministério da Saúde para definir as necessidades e estimular as pesquisas e a produção de insumos estratégicos para o Sistema Único de Saúde (SUS). Um compromisso público dessa dimensão nos convida a olhar para o passado recente a fim de tirar lições para o presente.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Cadernos de Saude Publica
- Vol. 39 (9) , e00073623
Open AccessRumo à equidade em saúde: por uma agenda de pesquisa e desenvolvimento e produção local orientada pelas múltiplas necessidades do Sistema Único de Saúde
Em seu discurso de posse, no dia 2 de janeiro de 2023, a nova ministra da saúde, Nísia Trindade Lima, apontou a produção local de insumos e o reforço do Complexo Econômico-Industrial da Saúde (CEIS, acronym in Portuguese) como algumas de suas prioridades, além da retomada do papel de coordenação do Ministério da Saúde para definir as necessidades e estimular as pesquisas e a produção de insumos estratégicos para o Sistema Único de Saúde (SUS). Um compromisso público dessa dimensão nos convida a olhar para o passado recente a fim de tirar lições para o presente.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Cadernos de Saude Publica
- Vol. 39 (9) , e00073623
Towards equity in health: for an agenda for research and development and local production driven by the multiple needs of the Brazilian Unified National Health System
Em seu discurso de posse, no dia 2 de janeiro de 2023, a nova ministra da saúde, Nísia Trindade Lima, apontou a produção local de insumos e o reforço do Complexo Econômico-Industrial da Saúde (CEIS, acronym in Portuguese) como algumas de suas prioridades, além da retomada do papel de coordenação do Ministério da Saúde para definir as necessidades e estimular as pesquisas e a produção de insumos estratégicos para o Sistema Único de Saúde (SUS). Um compromisso público dessa dimensão nos convida a olhar para o passado recente a fim de tirar lições para o presente.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Cadernos de Saude Publica
- Vol. 39 (9) , e00073623
Open AccessTowards equity in health: for an agenda for research and development and local production driven by the multiple needs of the Brazilian Unified National Health System
Em seu discurso de posse, no dia 2 de janeiro de 2023, a nova ministra da saúde, Nísia Trindade Lima, apontou a produção local de insumos e o reforço do Complexo Econômico-Industrial da Saúde (CEIS, acronym in Portuguese) como algumas de suas prioridades, além da retomada do papel de coordenação do Ministério da Saúde para definir as necessidades e estimular as pesquisas e a produção de insumos estratégicos para o Sistema Único de Saúde (SUS). Um compromisso público dessa dimensão nos convida a olhar para o passado recente a fim de tirar lições para o presente.
- Open Access
- 3 November 2021
- Published by Edinburgh University Library in Medicine Anthropology Theory
- Vol. 8 (2) , 1-25
Molecular Sovereignty: Building a Blood Screening Test for the Brazilian Nation
This article interrogates the relationship between the development of national diagnostic technologies and the exercise of sovereignty, by analysing a Brazilian project to produce a nucleic acid test (NAT) for the country’s blood screening programme. The concept of ‘molecular sovereignty’ is proposed to demonstrate that exercising sovereignty demands not only technological resources but also a sufficiently powerful and national imaginary to support local knowledge production as a means of advancing national healthcare priorities. First, this research article contextualises the political importance of blood safety for Brazil during its transition to democracy in the 1980s and the creation of its universal healthcare system. Then, it investigates how adopting the NAT led the state to invest in the production of a national technology. Third, the article unpacks the diagnostic test to consider how certain aspects of the project might ultimately strengthen the ability of global capital to cross national boundaries and create new markets. Lastly, it discusses how the project ended up creating a centralised and ‘closed’ system to avoid leaving the country vulnerable to the entry of global diagnostic companies. This case demonstrates how the molecularisation of blood, through the construction of a unified healthcare system driven by the constitutional right to health, can be deployed to construct imagined communities on the scale of a nation.
- 3 November 2021
- Published by Edinburgh University Library in Medicine Anthropology Theory
- Vol. 8 (2) , 1-25
Open AccessMolecular Sovereignty: Building a Blood Screening Test for the Brazilian Nation
This article interrogates the relationship between the development of national diagnostic technologies and the exercise of sovereignty, by analysing a Brazilian project to produce a nucleic acid test (NAT) for the country’s blood screening programme. The concept of ‘molecular sovereignty’ is proposed to demonstrate that exercising sovereignty demands not only technological resources but also a sufficiently powerful and national imaginary to support local knowledge production as a means of advancing national healthcare priorities. First, this research article contextualises the political importance of blood safety for Brazil during its transition to democracy in the 1980s and the creation of its universal healthcare system. Then, it investigates how adopting the NAT led the state to invest in the production of a national technology. Third, the article unpacks the diagnostic test to consider how certain aspects of the project might ultimately strengthen the ability of global capital to cross national boundaries and create new markets. Lastly, it discusses how the project ended up creating a centralised and ‘closed’ system to avoid leaving the country vulnerable to the entry of global diagnostic companies. This case demonstrates how the molecularisation of blood, through the construction of a unified healthcare system driven by the constitutional right to health, can be deployed to construct imagined communities on the scale of a nation.
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Cadernos de Saude Publica
- Vol. 37 (3) , e00277420
Testing COVID-19 in Brazil: fragmented efforts and challenges to expand diagnostic capacity at the Brazilian Unified National Health System
Since the first recorded case of COVID-19 on February 26, 2020, Brazil has seen an exponential growth in the number of cases and deaths. The national testing approach has been insufficient to correctly use this tool in the support of containing the epidemic in the country. In this communication, we discuss efforts and challenges to scale-up COVID-19 testing at the Brazilian Unified National Health System (SUS). This communication presents the initial results of the research project created to investigate the political, industrial, technological, and regulatory aspects that may affect the diagnostic and testing capacity for COVID-19 in Brazil. The paper draws on the review of academic literature, media publication, and collection of public data on tests purchase and regulation. It enlists initiatives to enhance PCR testing, national production and development of technologies, as well as regulatory measures to fast-track new tests. Our analysis indicates some points of reflection. Firstly, the lack of a consistent national strategy to fight COVID-19 exarcebated supply problems of diagnostic components. If the country was eventually able to circumvent this situation, it still faces a more structural dependency on the importation of diagnostic components. Secondly, the discontinued funding and distribution of tests may have implied health policy fragmentation and the growing importance of local governments and non-state actors to fighting the epidemics within SUS. Finally, initiatives established since the second semester of 2020 have expanded the testing capacity at SUS. However, it has not been sufficient to control the progress of the epidemic in the country.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Cadernos de Saude Publica
- Vol. 37 (3) , e00277420
Open AccessTesting COVID-19 in Brazil: fragmented efforts and challenges to expand diagnostic capacity at the Brazilian Unified National Health System
Since the first recorded case of COVID-19 on February 26, 2020, Brazil has seen an exponential growth in the number of cases and deaths. The national testing approach has been insufficient to correctly use this tool in the support of containing the epidemic in the country. In this communication, we discuss efforts and challenges to scale-up COVID-19 testing at the Brazilian Unified National Health System (SUS). This communication presents the initial results of the research project created to investigate the political, industrial, technological, and regulatory aspects that may affect the diagnostic and testing capacity for COVID-19 in Brazil. The paper draws on the review of academic literature, media publication, and collection of public data on tests purchase and regulation. It enlists initiatives to enhance PCR testing, national production and development of technologies, as well as regulatory measures to fast-track new tests. Our analysis indicates some points of reflection. Firstly, the lack of a consistent national strategy to fight COVID-19 exarcebated supply problems of diagnostic components. If the country was eventually able to circumvent this situation, it still faces a more structural dependency on the importation of diagnostic components. Secondly, the discontinued funding and distribution of tests may have implied health policy fragmentation and the growing importance of local governments and non-state actors to fighting the epidemics within SUS. Finally, initiatives established since the second semester of 2020 have expanded the testing capacity at SUS. However, it has not been sufficient to control the progress of the epidemic in the country.
- Open Access
- 1 March 2018
- Published by FapUNIFESP (SciELO) in Physis: Revista de Saúde Coletiva
- Vol. 28 (1)
A incorporação do teste diagnóstico baseado na amplificação de ácidos nucleicos (NAT) para triagem de sangue no SUS: arranjos tecnológicos para a nacionalização do “NAT brasileiro”
Os testes de ácidos nucleicos (NAT) são ferramentas complementares aos testes sorológicos para controle da transmissão de doenças infecciosas por meio de produtos obtidos a partir do sangue. Em 2002, um decreto do Ministério da Saúde tornou obrigatória a realização do NAT por todos os bancos de sangue, medida dificultada por razões como os custos necessários para a sua implantação. Como estratégia para a sua incorporação nos bancos de sangue ligados ao SUS, um consórcio público foi criado para desenvolver uma versão local do kit. A partir de métodos de pesquisa qualitativa, os autores analisam essa iniciativa, visando esmiuçar os detalhes da “nacionalização tecnológica” de um teste diagnóstico in vitro. O artigo descreve como o consórcio compreende o kit e como cada uma das tecnologias que o compõem são obtidas e reunidas no teste brasileiro. A relevância dessa análise é identificar quais os desafios e os limites à produção de testes in vitro para doenças infecciosas no Brasil, assim como a repercussão desse tipo de iniciativa para o sistema nacional de inovação em saúde.
- 1 March 2018
- Published by FapUNIFESP (SciELO) in Physis: Revista de Saúde Coletiva
- Vol. 28 (1)
Open AccessA incorporação do teste diagnóstico baseado na amplificação de ácidos nucleicos (NAT) para triagem de sangue no SUS: arranjos tecnológicos para a nacionalização do “NAT brasileiro”
Os testes de ácidos nucleicos (NAT) são ferramentas complementares aos testes sorológicos para controle da transmissão de doenças infecciosas por meio de produtos obtidos a partir do sangue. Em 2002, um decreto do Ministério da Saúde tornou obrigatória a realização do NAT por todos os bancos de sangue, medida dificultada por razões como os custos necessários para a sua implantação. Como estratégia para a sua incorporação nos bancos de sangue ligados ao SUS, um consórcio público foi criado para desenvolver uma versão local do kit. A partir de métodos de pesquisa qualitativa, os autores analisam essa iniciativa, visando esmiuçar os detalhes da “nacionalização tecnológica” de um teste diagnóstico in vitro. O artigo descreve como o consórcio compreende o kit e como cada uma das tecnologias que o compõem são obtidas e reunidas no teste brasileiro. A relevância dessa análise é identificar quais os desafios e os limites à produção de testes in vitro para doenças infecciosas no Brasil, assim como a repercussão desse tipo de iniciativa para o sistema nacional de inovação em saúde.
- 25 April 2014
- Published by Wiley in Developing World Bioethics
- Vol. 14 (2) , 101-108
Needs‐Driven Versus Market‐Driven Pharmaceutical Innovation: The Consortium for the Development of a New Medicine against Malaria in Brazil
The prevailing model for encouraging innovation based on patents and market-oriented raises at least two economic and ethical issues: it imposes barriers on individuals and developing countries governments' access to medicines by defining prices that do not match their income, and the unavailability of new or appropriate products to address the health problems of these populations. In the last decade, this scenario has undergone some changes due to the emergence of new actors, the contribution of aid resources, the introduction to the market of new products against neglected diseases, the development of new governmental healthcare policies and research programs, etc. One example of such initiatives is the Fixed-Dose Artesunate Combination Therapy (FACT) project consortium, which brought together institutions with different natures from both the North and the South, for the development of two antimalarial fixed-dose combinations recommended by the WHO - artesunate-amodiaquine (ASAQ) and artesunate-mefloquine (ASMQ). This paper proposes to describe and analyze the ASMQ consortium, which is the result of a new pharmaceutical development approach, based on a different paradigm - needs-driven instead of market-driven -, collaborative, with strategic participation of institutions from the South, funded by alternative resources (public and philanthropic). Thus, it represents an interesting object of study for bioethical debates on intellectual property and innovation, and its analysis is justified in light of the current debate on ways of stimulating needs-driven pharmaceutical innovation.
- 25 April 2014
- Published by Wiley in Developing World Bioethics
- Vol. 14 (2) , 101-108
Needs‐Driven Versus Market‐Driven Pharmaceutical Innovation: The Consortium for the Development of a New Medicine against Malaria in Brazil
The prevailing model for encouraging innovation based on patents and market-oriented raises at least two economic and ethical issues: it imposes barriers on individuals and developing countries governments' access to medicines by defining prices that do not match their income, and the unavailability of new or appropriate products to address the health problems of these populations. In the last decade, this scenario has undergone some changes due to the emergence of new actors, the contribution of aid resources, the introduction to the market of new products against neglected diseases, the development of new governmental healthcare policies and research programs, etc. One example of such initiatives is the Fixed-Dose Artesunate Combination Therapy (FACT) project consortium, which brought together institutions with different natures from both the North and the South, for the development of two antimalarial fixed-dose combinations recommended by the WHO - artesunate-amodiaquine (ASAQ) and artesunate-mefloquine (ASMQ). This paper proposes to describe and analyze the ASMQ consortium, which is the result of a new pharmaceutical development approach, based on a different paradigm - needs-driven instead of market-driven -, collaborative, with strategic participation of institutions from the South, funded by alternative resources (public and philanthropic). Thus, it represents an interesting object of study for bioethical debates on intellectual property and innovation, and its analysis is justified in light of the current debate on ways of stimulating needs-driven pharmaceutical innovation.